1. Market Research
  2. > Life Sciences Market Trends
Hydroxychloroquine Global Market Report 2020-30: Covid 19 Implications and Growth

Hydroxychloroquine Global Market Report 2020-30: Covid 19 Implications and Growth

  • July 2020
  • 200 pages
  • ID: 5932635
  • Format: PDF
  • The Business Research Company
Up to $800 off Until Dec 10th 2020

Summary

Table of Contents

Major players in the hydroxychloroquine market are Bayer AG, Dr. Reddy’s Laboratories, Zydus Cadila, Ipca Laboratories Ltd., Wallace Pharma, Teva, Mylan, Novartis, and Intas Pharmaceuticals.

The global hydroxychloroquine market is expected to grow from $718 million in 2019 to $980.1 million in 2020 at a compound annual growth rate (CAGR) of 36.5%. The growth is mainly attributed to the COVID-19 outbreak and the urgent need to treat the growing number of cases. With no effective therapeutics discovered so far, some of the existing drugs including hydroxychloroquine have been repurposed for COVID-19 infection treatment. Hydroxychloroquine is found to be effective against coronavirus in laboratory studies and in-vivo studies. The market is then expected to stabilize and reach $1,281.3 million in 2023 at a CAGR of 9.3%.

The hydroxychloroquine market consists of revenue generated by establishments through the sales of hydroxychloroquine drugs. It is an antimalarial drug used for the treatment of malaria, systemic lupus erythematosus (SLE), and rheumatoid arthritis. Hydroxychloroquine is used in combination with antibiotic azithromycin as a potential treatment for COVID-19.

North America is anticipated to be the largest region in the global hydroxychloroquine market by the end of 2020. Asia Pacific is expected to be the fastest-growing region in the forecast period.

Major players operating in the market are undertaking various strategic initiatives such as increasing production capacity and the expansion of manufacturing plants to meet the augmented global demand. For instance, in April 2020, Zydus Cadila announced that the company has ramped up its production capacity by 10 times for the production of hydroxychloroquine post the COVID 19 outbreak. Moreover, other manufacturers including IPCA Laboratories increased their monthly hydroxychloroquine production capacity five to six times during May 2020. Thus, the ramp-up of production capacities by major companies is a major trend shaping the hydroxychloroquine market.

The hydroxychloroquine market covered in this report is segmented by drug activity into anti-malarial; anti-rheumatic; lupus suppressant; anti Covid 19; others. It is also segmented by formulation into tablets; injection, by application into malaria; rheumatoid arthritis; lupus erythematosus; Covid-19; others and by distribution channel into hospital pharmacy; online pharmacy; specialty drug stores; retail pharmacy.

Side effects associated with the use of hydroxychloroquine drugs is predicted to limit market growth. The side effects associated with the use of hydroxychloroquine for the treatment of COVID patients include serious and potentially life-threatening heart rhythm problems. In April 2020, the US Food and Drug Administration warned against the side-effects of hydroxychloroquine and issued a safety communication regarding the side-effects of using the drug for COVID 19 outside of the hospital settings or clinical trials. Moreover, the World Health Organization (WHO) had suspended the clinical trials of hydroxychloroquine over safety concerns on the 25th of May 2020. However, the trials have been resumed by WHO on the 3rd of June 2020 after reviewing safety concerns. Nonetheless, the potential side effects restrict the use of hydroxychloroquine outside the hospital and clinical settings, thereby hindering the growth of the hydroxychloroquine market going forward.

In July 2019, Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, off-patent branded and generic establishment medicines business of Pfizer for an undisclosed amount to creating a new global pharmaceutical company. The new company is expected to transform and accelerate both companies’ ability to serve patients and expand their capabilities across more than 165 markets. Mylan N.V. was founded in 1961 and is a global generic and specialty pharmaceuticals company.

The increasing number of coronavirus cases has increased the demand for hydroxychloroquine in 2020. The demand for hydroxychloroquine is growing attributing to its use in the treatment of COVID-19 patients and in the ongoing clinical trials. The US Food and Drug Administration has authorized emergency use of hydroxychloroquine for the treatment of COVID-19 patients in the hospital or enrolled by clinical trials. According to the World Health Organization (WHO), there were more than 10 million confirmed cases of COVID-19, including more than 500,000 deaths reported as of 3rd July 2020, globally. USA, Brazil, Russia, UK, India and Spain are the countries most affected by the virus. Therefore, the continuous increase in coronavirus cases across the globe is surging the demand for hydroxychloroquine, generating higher revenues for the market during the period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

($4000)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on